PD-L1

[BMC Medicine] The effect of combined SFN and CAR-T cells was determined in vitro using a co-culture system and in vivo using a xenograft mouse model. They furthered validated the effects of combination therapy in patients with cancer.

[Critical Reviews in Oncology Hematology] The authors conduct a meta-analysis, showing that the addition of programmed death-1/programmed death ligand-1 (PD-L1) blockade to chemotherapy improves progression-free survival in PD-L1 positive metastatic TNBC patients, also in the intention-to-treat population.

[Cancer Immunology Research] Transcriptome analysis revealed that B7-H3 was highly expressed in PD-L1-low, non-immunoreactive high-grade serous ovarian cancer tumors, and its expression negatively correlated with an IFNγ signature, which reflected the tumor immune-reactivity.

[Journal For Immunotherapy of Cancer] Autologous tumor organoids were stimulated with T cells from the patients’ peripheral blood for two weeks to generate the organoid-primed T cells.

[Cancer Research] Emerging evidence indicates B cell activating factor (BAFF) to be an important cytokine for anti-tumor immunity. The authors generated a BAFF-overexpressing B16.F10 melanoma cell model and found that BAFF-expressing tumors grew more slowly in vivo than control tumors.

[Signal Transduction and Targeted Therapy] Golgi membrane protein 1 (GOLM1) was positively correlated with infiltrating tumor-associated macrophages expressed high levels of programmed death-ligand 1 (PD-L1) and CD8+ T cell suppression in hepatocellular carcinoma tissues.